Orrin Devinsky1, Daniel Friedman1, Robert B Duckrow2, Nathan B Fountain3, Ryder P Gwinn4, James W Leiphart5, Anthony M Murro6, Paul C Van Ness7. 1. NYU Langone Medical Center, New York, NY, USA. 2. Yale University School of Medicine, New Haven, CT, USA. 3. University of Virginia, Charlottesville, VA, USA. 4. Swedish Neuroscience Institute, Seattle, WA, USA. 5. Inova Medical Group, Mclean, VA, USA. 6. Augusta University Medical Center, Augusta, GA, USA. 7. Baylor College of Medicine, Houston, TX, USA.
Abstract
OBJECTIVE: To study the incidence and clinical features of sudden unexpected death in epilepsy (SUDEP) in patients treated with direct brain-responsive stimulation with the RNS System. METHODS: All deaths in patients treated in clinical trials (N = 256) or following U.S. Food and Drug Administration (FDA) approval (N = 451) through May 5, 2016, were adjudicated for SUDEP. RESULTS: There were 14 deaths among 707 patients (2208 postimplantation years), including 2 possible, 1 probable, and 4 definite SUDEP events. The rate of probable or definite SUDEP was 2.0/1000 (95% confidence interval [CI] 0.7-5.2) over 2036 patient stimulation years and 2.3/1000 (95% CI 0.9-5.4) over 2208 patient implant years. Stored electrocorticograms around the time of death were available for 4 patients with probable/definite SUDEP and revealed the following: frequent epileptiform activity ending abruptly (n = 2), no epileptiform activity or seizures (n = 1), and an electrographic and witnessed seizure with cessation of postictal electrocorticography (ECoG) activity associated with apnea and pulselessness (n = 1). SIGNIFICANCE: The SUDEP rate of 2.0/1000 patient stimulation years among patients treated with the RNS System is favorable relative to treatment-resistant epilepsy patients randomized to the placebo arm of add-on drug studies or with seizures after resective surgery. Our findings support that treatments that reduce seizures reduce SUDEP risk and that not all SUDEPs follow seizures.
OBJECTIVE: To study the incidence and clinical features of sudden unexpected death in epilepsy (SUDEP) in patients treated with direct brain-responsive stimulation with the RNS System. METHODS: All deaths in patients treated in clinical trials (N = 256) or following U.S. Food and Drug Administration (FDA) approval (N = 451) through May 5, 2016, were adjudicated for SUDEP. RESULTS: There were 14 deaths among 707 patients (2208 postimplantation years), including 2 possible, 1 probable, and 4 definite SUDEP events. The rate of probable or definite SUDEP was 2.0/1000 (95% confidence interval [CI] 0.7-5.2) over 2036 patient stimulation years and 2.3/1000 (95% CI 0.9-5.4) over 2208 patient implant years. Stored electrocorticograms around the time of death were available for 4 patients with probable/definite SUDEP and revealed the following: frequent epileptiform activity ending abruptly (n = 2), no epileptiform activity or seizures (n = 1), and an electrographic and witnessed seizure with cessation of postictal electrocorticography (ECoG) activity associated with apnea and pulselessness (n = 1). SIGNIFICANCE: The SUDEP rate of 2.0/1000 patient stimulation years among patients treated with the RNS System is favorable relative to treatment-resistant epilepsypatients randomized to the placebo arm of add-on drug studies or with seizures after resective surgery. Our findings support that treatments that reduce seizures reduce SUDEP risk and that not all SUDEPs follow seizures.
Authors: Inge C M Loonen; Nico A Jansen; Stuart M Cain; Maarten Schenke; Rob A Voskuyl; Andrew C Yung; Barry Bohnet; Piotr Kozlowski; Roland D Thijs; Michel D Ferrari; Terrance P Snutch; Arn M J M van den Maagdenberg; Else A Tolner Journal: Brain Date: 2019-02-01 Impact factor: 13.501
Authors: Hernán F J González; Saramati Narasimhan; Graham W Johnson; Kristin E Wills; Kevin F Haas; Peter E Konrad; Catie Chang; Victoria L Morgan; Mikail Rubinov; Dario J Englot Journal: Neurology Date: 2021-01-13 Impact factor: 9.910
Authors: Laura Vilella; Nuria Lacuey; Johnson P Hampson; M R Sandhya Rani; Rup K Sainju; Daniel Friedman; Maromi Nei; Kingman Strohl; Catherine Scott; Brian K Gehlbach; Bilal Zonjy; Norma J Hupp; Anita Zaremba; Nassim Shafiabadi; Xiuhe Zhao; Victoria Reick-Mitrisin; Stephan Schuele; Jennifer Ogren; Ronald M Harper; Beate Diehl; Lisa Bateman; Orrin Devinsky; George B Richerson; Philippe Ryvlin; Samden D Lhatoo Journal: Neurology Date: 2018-12-19 Impact factor: 11.800